For Q1 FY2026 (ended March 31, 2026), United Therapeutics reported revenue of $781.5 million, a slight decrease of 1.6% year-over-year. Net income was $274.9 million, down 14.7% from the prior year, while operating income fell 14.9% to $325.8 million. Diluted EPS was $5.82, a 12.2% decline. The company held $1.28 billion in cash and $5.90 billion in equity, with no long-term debt reported.
•Revenue: $781.5M (-1.6% YoY)
•Net income: $274.9M (-14.7% YoY)
•Operating income: $325.8M (-14.9% YoY)
•Diluted EPS: $5.82 (-12.2% YoY)
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
United Therapeutics provides the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and globally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges.
Its portfolio also includes Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer, Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise, Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients, and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma Remunity Pump, which contains a pump and separate controller for Remodulin.
Additionally, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis Xenografts, which are development-stage organ products, as well as preclinical products, including EVLP/CLES, for lung transplant.
Its portfolio also includes UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation, ULobe, for allogeneic regenerative medicine, ULung, for autologous regenerative medicine, IVIVA Kidney, for autologous regenerative medicine, miroliver, for allogeneic regenerative medicine, and mirokidney, for allogeneic regenerative medicine.
It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil. Its portfolio also includes MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device, and Arena Pharmaceuticals, Inc. to develop Ralinepag. Founded in 1996, the company is headquartered in Silver Spring, Maryland.
What does United Therapeutics Corporation (UTHR) do?
United Therapeutics Corporation is a healthcare company focused on developing and commercializing products for chronic and life-threatening diseases, primarily pulmonary arterial hypertension (PAH). Its portfolio includes Tyvaso DPI (an inhaled dry powder), Nebulized Tyvaso (an inhaled solution), Remodulin injection, Orenitram tablets, and Adcirca, an oral PDE-5 inhibitor. It also markets Unituxin for high-risk neuroblastoma and the Remunity Pump for Remodulin delivery. Additionally, the company is developing treatments for idiopathic pulmonary fibrosis and advancing xenotransplantation products like gene-edited porcine kidneys and hearts, as well as regenerative medicine programs such as ULung and miroliver.
Where is United Therapeutics (UTHR) listed and in which currency?
United Therapeutics Corporation is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol UTHR. Its shares are traded in US dollars (USD), reflecting its primary listing in the United States. The company is headquartered in the United States and operates globally, but its stock is denominated in USD, making it accessible to investors through US-based exchanges.
What sector and industry does United Therapeutics (UTHR) belong to?
United Therapeutics operates in the Healthcare sector and is classified under the Drug Manufacturers - Specialty & Generic industry. This means the company specializes in developing and manufacturing drugs for specific, often rare diseases, as opposed to broad-market pharmaceuticals. Its focus on specialty drugs for pulmonary arterial hypertension and other chronic conditions aligns with this industry category, and it also engages in innovative areas like xenotransplantation and regenerative medicine.
What are the main products of United Therapeutics (UTHR) for pulmonary arterial hypertension?
United Therapeutics offers a range of products for pulmonary arterial hypertension (PAH). These include Tyvaso DPI, an inhaled dry powder delivered via pre-filled cartridges; Nebulized Tyvaso, an inhaled solution using an ultrasonic nebulizer; Remodulin (treprostinil) injection; Orenitram, an oral tablet form of treprostinil; and Adcirca, an oral PDE-5 inhibitor. Additionally, the Remunity Pump system is used for continuous subcutaneous infusion of Remodulin. The company is also developing RemunityPRO Pump and Ralinepag for PAH, as well as exploring Nebulized Tyvaso for idiopathic pulmonary fibrosis.
Does United Therapeutics (UTHR) operate globally or only in the US?
United Therapeutics Corporation operates both in the United States and globally, as indicated in its description summary. While its headquarters and primary listing are in the US, the company markets and develops products for patients worldwide. Its products, such as Tyvaso, Remodulin, and Unituxin, are available in multiple countries, and its research programs, including xenotransplantation and regenerative medicine, have international implications. The company's global reach is supported by its presence in various markets, though specific geographic revenue breakdowns are not provided.